Role of PI3K/AKT pathway in cancer: the framework of malignant behavior

被引:441
|
作者
Jiang, Ningni [1 ,2 ,3 ]
Dai, Qijie [1 ,2 ,3 ]
Su, Xiaorui [1 ,2 ,3 ]
Fu, Jianjiang [1 ,2 ,3 ]
Feng, Xuancheng [1 ,2 ,3 ]
Peng, Juan [1 ,2 ,3 ,4 ]
机构
[1] Guangzhou Med Univ, Dept Pathol, Affiliated Hosp 3, 63 Duobao Rd, Guangzhou 510150, Peoples R China
[2] Guangzhou Med Univ, Clin Sch 3, Guangzhou 510150, Peoples R China
[3] Guangdong Higher Educ Inst, Key Lab Reprod & Genet, Guangzhou 510150, Peoples R China
[4] Wake Forest Sch Med, Dept Microbiol & Immunol, Winston Salem, NC 27157 USA
基金
中国国家自然科学基金;
关键词
PI3K; AKT; PTEN; Cancer; Targeted therapy; EPITHELIAL-MESENCHYMAL TRANSITION; PROMOTES CELL-PROLIFERATION; PAPILLARY THYROID-CANCER; ACUTE MYELOID-LEUKEMIA; PROTEIN-KINASE B; RELAPSED/REFRACTORY MULTIPLE-MYELOMA; AKT INHIBITOR AFURESERTIB; HUMAN BLADDER-CANCER; PROSTATE-CANCER; SIGNALING PATHWAY;
D O I
10.1007/s11033-020-05435-1
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Given that the PI3K/AKT pathway has manifested its compelling influence on multiple cellular process, we further review the roles of hyperactivation of PI3K/AKT pathway in various human cancers. We state the abnormalities of PI3K/AKT pathway in different cancers, which are closely related with tumorigenesis, proliferation, growth, apoptosis, invasion, metastasis, epithelial-mesenchymal transition, stem-like phenotype, immune microenvironment and drug resistance of cancer cells. In addition, we investigated the current clinical trials of inhibitors against PI3K/AKT pathway in cancers and found that the clinical efficacy of these inhibitors as monotherapy has so far been limited despite of the promising preclinical activity, which means combinations of targeted therapy may achieve better efficacies in cancers. In short, we hope to feature PI3K/AKT pathway in cancers to the clinic and bring the new promising to patients for targeted therapies.
引用
收藏
页码:4587 / 4629
页数:43
相关论文
共 50 条
  • [21] Exploiting the PI3K/AKT pathway for cancer drug discovery
    Hennessy, BT
    Smith, DL
    Ram, PT
    Lu, YL
    Mills, GB
    NATURE REVIEWS DRUG DISCOVERY, 2005, 4 (12) : 988 - 1004
  • [22] MicroRNAs and the PTEN/PI3K/Akt pathway in gastric cancer
    Hu, Mingli
    Zhu, Shixuan
    Xiong, Shengwei
    Xue, Xingxing
    Zhou, Xiaodong
    ONCOLOGY REPORTS, 2019, 41 (03) : 1439 - 1454
  • [23] PI3K/Akt/mTOR pathway as a target for cancer therapy
    Morgensztern, D
    McLeod, HL
    ANTI-CANCER DRUGS, 2005, 16 (08) : 797 - 803
  • [24] Targeting the PI3K/AKT/mTOR pathway in ovarian cancer
    Musa, Fernanda
    Schneider, Robert
    TRANSLATIONAL CANCER RESEARCH, 2015, 4 (01) : 97 - 106
  • [25] Advances in the role of microRNAs associated with the PI3K/AKT signaling pathway in lung cancer
    Wang, Yanting
    Zhang, Tao
    He, Xin
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [26] Activation of PI3K/Akt/mTOR Pathway and Dual Inhibitors of PI3K and mTOR in Endometrial Cancer
    Chen, Jiezhong
    Zhao, Kong-Nan
    Li, Rui
    Shao, Renfu
    Chen, Chen
    CURRENT MEDICINAL CHEMISTRY, 2014, 21 (26) : 3070 - 3080
  • [27] Deciphering the Role of PI3K/Akt/mTOR Pathway in Breast Cancer Biology and Pathogenesis
    McAuliffe, Priscilla F.
    Meric-Bernstam, Funda
    Mills, Gordon B.
    Gonzalez-Angulo, Ana M.
    CLINICAL BREAST CANCER, 2010, 10 : S59 - S65
  • [28] The versatile role of curcumin in cancer prevention and treatment: A focus on PI3K/AKT pathway
    Hamzehzadeh, Leila
    Atkin, Stephen L.
    Majeed, Muhammed
    Butler, Alexandra E.
    Sahebkar, Amirhossein
    JOURNAL OF CELLULAR PHYSIOLOGY, 2018, 233 (10) : 6530 - 6537
  • [29] Role of regulatory miRNAs of the PI3K/AKT signaling pathway in the pathogenesis of breast cancer
    Rahmani, Farzad
    Ferns, Gordon A.
    Talebian, Sahar
    Nourbakhsh, Mahnaz
    Avan, Amir
    Shahidsales, Soodabeh
    GENE, 2020, 737
  • [30] Role of the PI3K/Akt pathway in cadmium induced malignant transformation of normal prostate epithelial cells
    Kulkarni, Priyanka
    Dasgupta, Pritha
    Bhat, Nadeem S.
    Hashimoto, Yutaka
    Saini, Sharanjot
    Shahryari, Varahram
    Yamamura, Soichiro
    Shiina, Marisa
    Tanaka, Yuichiro
    Dahiya, Rajvir
    Majid, Shahana
    TOXICOLOGY AND APPLIED PHARMACOLOGY, 2020, 409